BioCryst Pharmaceuticals

BioCryst Pharmaceuticals EBIT

The EBIT of BioCryst Pharmaceuticals (BCRX) as of Nov 5, 2026 is 340.99 M USD. In the previous year, EBIT was -3.18 M USD — a change of -10,809.45% (higher).

EBIT

340.99 MUSD

YoY

-10,809.45%

Last updated:

In 2025, BioCryst Pharmaceuticals's EBIT was 340.99 M USD, a -10,809.45% increase from the -3.18 M USD EBIT recorded in the previous year.

The BioCryst Pharmaceuticals EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-117.99 M USD
Jan 1, 2024
-3.18 M USD
Jan 1, 2025
340.99 M USD
Jan 1, 2026 (e)
-402.46 M USD
Jan 1, 2027 (e)
248.42 M USD
Jan 1, 2028 (e)
259.06 M USD
Jan 1, 2029 (e)
356.87 M USD
Jan 1, 2030 (e)
492.84 M USD
The BioCryst Pharmaceuticals EBIT history
YEAREBITYoY
est492.84 MUSD+38.10%
est356.87 MUSD+37.76%
est259.06 MUSD+4.28%
est248.42 MUSD-161.73%
est-402.46 MUSD-218.03%
340.99 MUSD-10,809.45%
-3.18 MUSD-97.30%
-117.99 MUSD-21.56%
-150.42 MUSD+22.71%
-122.58 MUSD-31.03%
-177.73 MUSD+78.71%
-99.46 MUSD+5.56%
-94.22 MUSD+61.80%
-58.23 MUSD+17.76%
-49.45 MUSD+25.37%
-39.44 MUSD-13.82%
-45.77 MUSD+49.01%
-30.72 MUSD-9.36%
-33.89 MUSD-31.66%
-49.59 MUSD+49.19%
-33.24 MUSD+141.93%
-13.74 MUSD-49.43%
-27.16 MUSD-15.85%
-32.28 MUSD-31.29%
-46.98 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCryst Pharmaceuticals Revenue

BioCryst Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
331.41 M USD
-117.99 M USD
-226.54 M USD
Jan 1, 2024
450.71 M USD
-3.18 M USD
-88.88 M USD
Jan 1, 2025
874.84 M USD
340.99 M USD
263.86 M USD
Jan 1, 2026 (e)
710.08 M USD
-402.46 M USD
-473.72 M USD
Jan 1, 2027 (e)
742.66 M USD
248.42 M USD
115.25 M USD
Jan 1, 2028 (e)
834.65 M USD
259.06 M USD
119.88 M USD
Jan 1, 2029 (e)
976.26 M USD
356.87 M USD
195.47 M USD
Jan 1, 2030 (e)
1.16 B USD
492.84 M USD
297.05 M USD

BioCryst Pharmaceuticals Margins

BioCryst Pharmaceuticals stock margins

The BioCryst Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioCryst Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioCryst Pharmaceuticals.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
98.59 %
-35.60 %
-68.36 %
Jan 1, 2024
97.23 %
-0.71 %
-19.72 %
Jan 1, 2025
97.82 %
38.98 %
30.16 %
Jan 1, 2026 (e)
97.82 %
-56.68 %
-66.71 %
Jan 1, 2027 (e)
97.82 %
33.45 %
15.52 %
Jan 1, 2028 (e)
97.82 %
31.04 %
14.36 %
Jan 1, 2029 (e)
97.82 %
36.55 %
20.02 %
Jan 1, 2030 (e)
97.82 %
42.37 %
25.54 %

BioCryst Pharmaceuticals Stock analysis

What does BioCryst Pharmaceuticals do? BioCryst Pharmaceuticals Inc. is a biopharmaceutical company based in Durham, North Carolina, USA. The company was founded in 1986 by Charles Bugg and George Lipscomb, with the aim of developing new therapies for serious diseases. BioCryst has been listed on the stock exchange since 1991 and has continuously evolved since then. BioCryst's business model is based on the discovery and development of new drugs for rare and serious diseases. The company specializes in oncology, infectious diseases, and rare genetic disorders, and works closely with academic institutions and pharmaceutical partners to develop innovative therapies. In oncology, BioCryst focuses on the development of therapies for solid tumors and malignant blood disorders. One of the most promising candidates is BCX9930, a novel C5 complement inhibitor developed for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases. In the field of infectious diseases, BioCryst is working on the development of new therapies against viral diseases such as influenza, RSV, and Ebola. The company has entered into a cooperation with the Japanese company Shionogi to bring the influenza inhibitor Peramivir to the market. Peramivir is the only intravenous influenza inhibitor approved in the United States. Another important area for BioCryst is rare genetic diseases. The company has launched a promising program to develop therapies for the rare genetic metabolic disorder phenylketonuria (PKU). The program is being conducted in collaboration with the National Institutes of Health (NIH) and aims to enable the development of an enzyme replacement therapy. BioCryst also has a strong pipeline of drugs in the development phase. Promising candidates include the oral protein kinase inhibitor BCX9250 for the treatment of solid tumors and the antibody BCX9932 for the treatment of coronavirus infections. The company has a solid financial foundation and is committed to expanding its pipeline and forming new partnerships. BioCryst has expanded its research and development activities and works closely with academic institutions and pharmaceutical companies to develop innovative therapies. Overall, BioCryst has established itself as a promising biopharmaceutical company focused on the development of new drugs for rare and serious diseases. The company has a strong pipeline of drug candidates and works closely with its partners to fulfill its mission of improving the lives of patients by providing innovative therapies. BioCryst Pharmaceuticals is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing BioCryst Pharmaceuticals's EBIT

BioCryst Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of BioCryst Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

BioCryst Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in BioCryst Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about BioCryst Pharmaceuticals stock

EBIT of BioCryst Pharmaceuticals is 340.99 M USD in 2025.

EBIT of BioCryst Pharmaceuticals changed from -3.18 M USD to 340.99 M USD, representing a -10,809.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT BioCryst Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's BioCryst Pharmaceuticals historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioCryst Pharmaceuticals

All Key Metrics — BioCryst Pharmaceuticals